Legend Biotech Corporation

NasdaqGS:LEGN Stock Report

Market Cap: US$6.0b

Legend Biotech Valuation

Is LEGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LEGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$124.15
Fair Value
74.3% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: LEGN ($31.96) is trading below our estimate of fair value ($124.15)

Significantly Below Fair Value: LEGN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LEGN?

Key metric: As LEGN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LEGN. This is calculated by dividing LEGN's market cap by their current revenue.
What is LEGN's PS Ratio?
PS Ratio7.4x
SalesUS$796.84m
Market CapUS$5.97b

Price to Sales Ratio vs Peers

How does LEGN's PS Ratio compare to its peers?

The above table shows the PS ratio for LEGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average22.4x
RYTM Rhythm Pharmaceuticals
46.9x43.92%US$7.4b
PTGX Protagonist Therapeutics
23x22.47%US$4.7b
TGTX TG Therapeutics
11.1x26.79%US$5.1b
MIRM Mirum Pharmaceuticals
8.6x17.74%US$3.7b
LEGN Legend Biotech
7.4x26.55%US$6.0b

Price-To-Sales vs Peers: LEGN is good value based on its Price-To-Sales Ratio (7.4x) compared to the peer average (22.4x).

Price to Sales Ratio vs Industry

How does LEGN's PS Ratio compare vs other companies in the US Biotechs Industry?

156 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMGN Amgen
4.6x2.20%US$159.25b
REGN Regeneron Pharmaceuticals
4.2x6.22%US$59.02b
BIIB Biogen
2.1x-1.19%US$20.86b
INCY Incyte
3.7x1.82%US$17.05b
LEGN 7.4xIndustry Avg. 11.3xNo. of Companies156PS020406080100+
156 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LEGN is good value based on its Price-To-Sales Ratio (7.4x) compared to the US Biotechs industry average (11.3x).

Price to Sales Ratio vs Fair Ratio

What is LEGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LEGN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.4x
Fair PS Ratio4.3x

Price-To-Sales vs Fair Ratio: LEGN is expensive based on its Price-To-Sales Ratio (7.4x) compared to the estimated Fair Price-To-Sales Ratio (4.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LEGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$31.96
US$75.06
+134.85%
16.30%US$94.00US$54.00n/a16
Oct ’26US$32.66
US$76.62
+134.59%
14.93%US$94.00US$54.00n/a16
Sep ’26US$34.73
US$77.27
+122.48%
14.52%US$94.00US$54.00n/a18
Aug ’26US$38.80
US$76.29
+96.62%
15.30%US$94.00US$54.00n/a19
Jul ’26US$36.29
US$75.49
+108.02%
15.73%US$94.00US$53.12n/a20
Jun ’26US$28.95
US$76.73
+165.03%
16.19%US$95.00US$53.12n/a21
May ’26US$33.96
US$77.99
+129.66%
15.81%US$95.00US$53.12n/a21
Apr ’26US$31.52
US$78.01
+147.50%
15.82%US$95.00US$53.12n/a21
Mar ’26US$35.01
US$79.26
+126.38%
14.28%US$95.00US$53.12n/a21
Feb ’26US$38.10
US$79.83
+109.52%
13.85%US$95.00US$53.12n/a21
Jan ’26US$32.54
US$81.85
+151.53%
12.28%US$95.00US$60.00n/a20
Dec ’25US$42.07
US$82.50
+96.10%
11.35%US$95.00US$60.00n/a20
Nov ’25US$44.36
US$83.15
+87.44%
11.44%US$95.00US$60.00n/a20
Oct ’25US$47.48
US$82.98
+74.78%
11.71%US$95.00US$60.00US$32.6619
Sep ’25US$57.55
US$82.93
+44.10%
11.74%US$95.00US$60.00US$34.7319
Aug ’25US$55.00
US$82.63
+50.24%
12.19%US$95.00US$60.00US$38.8019
Jul ’25US$46.02
US$82.50
+79.28%
12.24%US$95.00US$60.00US$36.2919
Jun ’25US$40.01
US$83.03
+107.53%
11.97%US$95.00US$60.00US$28.9518
May ’25US$43.98
US$86.33
+96.29%
7.92%US$95.00US$65.00US$33.9618
Apr ’25US$57.22
US$86.45
+51.09%
7.90%US$95.00US$65.00US$31.5217
Mar ’25US$65.53
US$86.29
+31.68%
9.27%US$100.00US$65.00US$35.0115
Feb ’25US$56.22
US$86.29
+53.48%
9.27%US$100.00US$65.00US$38.1015
Jan ’25US$60.17
US$86.57
+43.88%
9.18%US$100.00US$65.00US$32.5415
Dec ’24US$59.99
US$87.69
+46.17%
6.54%US$100.00US$76.00US$42.0714
Nov ’24US$66.81
US$87.67
+31.22%
6.96%US$100.00US$76.00US$44.3612
Oct ’24US$67.17
US$88.18
+31.28%
6.66%US$100.00US$76.00US$47.4811
US$75.06
Fair Value
57.4% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/17 20:19
End of Day Share Price 2025/10/17 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Legend Biotech Corporation is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Suranjit MukherjeeBTIG
Justin ZelinBTIG